Cytomegalovirus reactivation accompanied by varicella zoster virus reactivation or reinfection in an adult patient of multiple myeloma during bortezomib therapy

2017 ◽  
Vol 45 (1) ◽  
pp. 108-109 ◽  
Author(s):  
Tomoyuki Hioki ◽  
Hiroyuki Takama ◽  
Sumiko Makita ◽  
Kazuko Watanabe ◽  
Daisuke Watanabe ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adult Patient ◽  
Varicella Zoster Virus ◽  
Virus Reactivation ◽  
Varicella Zoster ◽  
Cytomegalovirus Reactivation

scholarly journals Importance of Compliance With Guidelines for the Prevention of Varicella-Zoster Virus Reactivation in Multiple Myeloma

In Vivo ◽  
2021 ◽  
Vol 35 (6) ◽  
pp. 3289-3296
Author(s):  
YASUKATA OHASHI ◽  
MEGUMI YATABE ◽  
DAISUKE NIIJIMA ◽  
ARINA IMAMURA ◽  
YOSHIYUKI NAGAYAMA ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Varicella Zoster Virus ◽  
Virus Reactivation ◽  
Varicella Zoster

scholarly journals GUILLAIN-BARRÉ SYNDROME INDUCED BY VARICELLA ZOSTER VIRUS REACTIVATION IN A PATIENT WITH MULTIPLE MYELOMA

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A699
Author(s):  
Dmitriy Generalov ◽  
Elise Hsu ◽  
Winnie Chu ◽  
Garry Lachhar ◽  
Christina Le ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Varicella Zoster Virus ◽  
Guillain Barre Syndrome ◽  
Virus Reactivation ◽  
Varicella Zoster ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Varicella Zoster Virus Reactivation Can be Prevented Very Well By Valacyclovir in Patients with Multiple Myeloma Treated with Bortezomib

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5655-5655
Author(s):  
Qi Wei ◽  
Yongqiang Wei ◽  
Ru Feng ◽  
Xiaolei Wei
Keyword(s):  
Multiple Myeloma ◽  
Adverse Events ◽  
Varicella Zoster Virus ◽  
Median Duration ◽  
Conflicts Of Interest ◽  
Significant Risk ◽  
Virus Reactivation ◽  
Varicella Zoster ◽  
Bortezomib Treatment ◽  
Grade 3

Abstract BACKGROUND: Bortezomib is associated with a significant risk of Varicella zoster virus (VZV) reactivation in patients with multiple myeloma (MM). There are some reports that acyclovir or valacycclovir reduces the risk of VZV reactivation. We assessed whether VZV reactivation could be prevented by valacyclovir at a dose of 300 mg bid. PATIENTS AND METHODS: We retrospectively evaluated 108 patients with MM who received bortezomib and valacyclovir prophylaxis at the Nanfang Hospital from 2015 to 2017. Patients received valacyclovir prophylaxis orally at a dose of 300 mg bid, without cessation until finishing the whole course of bortezomib treatment. RESULTS: The median age was 56 years (range=37-84 years). 57 patients were male and 51 were female. The median bortezomib dose was 31.2 mg/m2(range=5.2-83.2 mg/m2). All patients also received corticosteroids. The median duration of valacyclovir prophylaxis was 333 days (range=38-724 days) and the median valacyclovir dose was 199.8 g (range=22.8-434.4 g). VZV reactivation did not develop in any patient during valacyclovir prophylaxis. Adverse events over grade 3 associated with valacyclovir were not observed. CONCLUSION: Valacyclovir at a dose of 300 mg bid appears to be effective at preventing VZV reactivation and was well-tolerated by patients with MM treated with bortezomib. Disclosures No relevant conflicts of interest to declare.

scholarly journals Analysis of T Cell Responses during Active Varicella-Zoster Virus Reactivation in Human Ganglia

2013 ◽  
Vol 88 (5) ◽  
pp. 2704-2716 ◽  
Author(s):  
M. Steain ◽  
J. P. Sutherland ◽  
M. Rodriguez ◽  
A. L. Cunningham ◽  
B. Slobedman ◽  
...  
Keyword(s):  
T Cell ◽  
Varicella Zoster Virus ◽  
T Cell Responses ◽  
Virus Reactivation ◽  
Varicella Zoster ◽  
Cell Responses

scholarly journals A Case Report of Acute Severe Myelitis and Meningitis Secondary to Varicella Zoster Virus Reactivation in a Patient with Acquired Immunodeficiency Syndrome

2021 ◽  
Author(s):  
Victor A Novelo-Hernández ◽  
Marco Cárdenas ◽  
Claudia Torres-González ◽  
Patricio Garcia-Espinosa ◽  
Rómulo Ramirez ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Varicella Zoster Virus ◽  
Acquired Immunodeficiency Syndrome ◽  
Clinical Manifestations ◽  
Virus Reactivation ◽  
Neck Stiffness ◽  
Varicella Zoster ◽  
Wide Range ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

Background: Myelitis post Herpes-Zoster is a rare condition that is typically associated with immunocompromised states. It usually starts as an acute loss of sensory and motor functions below the affected spinal cord level. The condition can range in severity from a mild to a fatal presentation. Other neurological complications include meningitis, atypical presentations should encourage the search for undiagnosed immunosuppression states. The Case: We describe the case of a 42-year-old man, previously undiagnosed with HIV, who developed acute myelitis and meningitis after the appearance of the classic zoster lesions. On lumbar puncture and subsequent CSF analysis, the patient was found to have Froin’s Syndrome. The patient was initiated with ceftriaxone, vancomycin, and acyclovir regimen and prophylactic antiphymic treatment was also added. After 14 days in the hospital, the fever, headache, and neck stiffness subsided while the sphincter function and lower limb paraplegia did not improve.   Conclusion: Varicella zoster virus reactivation suggests underlying immunosuppression. This case demonstrates the importance of being cognizant to the wide range of clinical manifestations that may suggest spinal cord involvement after clinical reactivation. Furthermore, physicians also need to be mindful that Acquired Immunodeficiency Syndrome (AIDS) and other immunodeficiency states could present with atypical clinical manifestations.

Sign in / Sign up

Export Citation Format

Share Document